DM
MNPR icon

Deerfield Management’s Monopar Therapeutics MNPR Stock Holding History

Deerfield Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30M Hold
323,745
– – 0.31% 54
2026
Q1 		$17.7M Buy
323,745
+153,187
+90% +$9.25M 0.21% 64
2025
Q4 		$11.1M Buy
170,558
+10,793
+7% +$882K 0.14% 66
2025
Q3 		$13M Buy
+159,765
New +$7.14M 0.2% 64

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Deerfield Management's MNPR Position: Q2 2026 in Review

Deerfield Management held its Monopar Therapeutics (MNPR) position steady in Q2 2026 at 323,745 shares worth $30M. The position accounts for 0.31% of the portfolio, ranked #54.

Deerfield Management first reported a position in MNPR in Q3 2025 and has held it in 4 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Deerfield Management held 323,745 shares of Monopar Therapeutics worth $30M as of Q2 2026.
  • Deerfield Management left its Monopar Therapeutics share count unchanged in Q2 2026.
  • Monopar Therapeutics made up 0.31% of Deerfield Management's portfolio in Q2 2026, its #54 holding.
  • Deerfield Management first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.